Analytical Data
-
Gene name
BE2S1
- Application
-
Alternative Names
Alternative name(s): Allergen: Ber e 1 Cleaved into the following 2 chains: 2S sulfur-rich seed storage protein small chain 1 Alternative name(s): 2S albumin 1 small subunit 2S sulfur-rich seed storage protein large chain 1B Alternative name(s): 2S albumin 1 large subunit
-
Species
Brazil nut
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04403
-
Expression Region
37-142aa
-
Molecular Weight
14.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BE2S1 is a recombinant protein that has garnered attention in recent years due to its potential applications in various biomedical fields, particularly in cancer research and therapeutic development. This protein is derived from the BE2 neuroblastoma cell line, which is known for its aggressive behavior and resistance to conventional therapies. The study of BE2S1 focuses on understanding its structure, function, and interactions within cellular environments. Researchers aim to elucidate its role in tumorigenesis and metastasis, as well as its potential as a biomarker for diagnosis and prognosis in neuroblastoma patients. Additionally, BE2S1 presents opportunities for developing novel therapeutic strategies, including targeted therapies that can inhibit its function or modulate its pathways. Given the pressing need for more effective cancer treatments, the investigation into BE2S1 is crucial for contributing to the broader understanding of neuroblastoma pathophysiology and for advancing precision medicine approaches tailored to individual patient profiles. As a recombinant protein, BE2S1 can be produced in controlled laboratory conditions, facilitating large-scale studies and the characterization of its biological properties, paving the way for innovative diagnostics and therapies in oncology.
